The euphoria that lifted Moderna shares to a record high on Wednesday has given way to a sharp correction, with the stock shedding roughly a fifth of its value in European trading on Thursday. The pullback, however, looks less like a verdict on the company’s prospects than a natural reset after one of the most explosive sessions in the biotech’s recent history.
At 118.22 euros, the shares now sit exactly 21 percent below the 52-week peak of 149.42 euros reached just 24 hours earlier. The retreat follows a rally that saw the company’s market capitalization swell by nearly $40 billion in a single day, according to Reuters, with the stock at one point climbing as much as 160 percent.
A Scientific Breakthrough Reshapes the Debate
The volatility traces back to a landmark announcement from Moderna and its partner Merck, known as MSD in Europe. Their Phase 3 trial, dubbed INTerpath-001, met both its primary and secondary endpoints, validating the personalized mRNA cancer vaccine Intismeran (mRNA-4157) when used alongside the immunotherapy Keytruda.
The study enrolled 1,137 patients with high-risk melanoma at stages IIB through IV, all of whom had undergone complete surgical removal of their tumors. Results showed a statistically significant improvement in recurrence-free survival, while the distant metastasis-free survival endpoint was also achieved.
Earlier Phase 2b data had already hinted at the therapy’s potential, showing the combination cut the risk of relapse or death by 49 percent compared with Keytruda alone, while reducing the risk of metastasis by 59 percent.
The implications extend well beyond melanoma. Moderna is already running additional trials exploring the technology in bladder, kidney, pancreatic, stomach, and colorectal cancers. A regulatory filing for the melanoma indication could come as early as next year, though CEO Stéphane Bancel has suggested approval might arrive by early 2027.
Analysts Scramble to Catch Up
The clinical success triggered a wave of target price revisions as sell-side firms recalibrated their views on the mRNA platform’s potential beyond infectious diseases. Bank of America upgraded the stock with a target of $170, a dramatic increase from its previous $40 price objective. Goldman Sachs lifted its target from $67 to $120, with analysts noting the data could pave the way for an entirely new class of treatments.
Should investors sell immediately? Or is it worth buying Moderna?
Yet the consensus remains cautious. Barclays reaffirmed its “Hold” rating with a $48 target on Tuesday, while Citi maintained a neutral stance on August 3 and JPMorgan kept a “Sell” recommendation on August 4 — though all three assessments predated the trial results.
Technical Forces Amplify the Swings
Wednesday’s surge was compounded by a massive short squeeze. Short interest had stood at roughly 14 percent of the float before the data release, and the sharp upward move left short sellers nursing billions in losses, according to market estimates. Thursday’s decline is being interpreted primarily as profit-taking following that extraordinary run, which had seen the stock gain 151 percent over the preceding seven sessions.
Beyond Oncology: A Second Catalyst
The cancer vaccine is not the only arrow in Moderna’s quiver. On August 6, the FDA approved the company’s mRNA-based seasonal flu vaccine for adults aged 50 and older — the first such shot of its kind to receive regulatory clearance anywhere in the world. The decision followed a late-stage trial involving more than 40,000 adults. Those aged 50 to 64 received a standard approval, while the over-65 cohort was granted accelerated approval, with Moderna required to submit additional data from a supplementary study for that age group.
The approval strengthens Moderna’s foothold in the respiratory vaccines market, which has historically been dominated by more traditional manufacturing techniques.
What Comes Next
The near-term focus now shifts to the regulatory pathway for the melanoma therapy. Manufacturing logistics will be a key consideration: each personalized vaccine currently takes about six weeks to produce per patient. Full data from the INTerpath-001 study are scheduled for presentation at a medical conference in October, which could provide further clarity on the treatment’s efficacy profile.
For now, the market appears to be catching its breath after a historic 48 hours — with the underlying story of a maturing mRNA platform increasingly difficult to ignore.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from August 20 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 20.
Moderna: Buy or sell? Read more here...
